Related Experiment Videos
Drug sensitivity of different tumor lesions from the same patient evaluated by a short-term assay
N Zaffaroni1, R Silvestrini, O Sanfilippo
1Divisione di Oncologia Sperimentale C, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan.
Abstract:
A short-term antimetabolic assay, which considers the interference with [3H]thymidine incorporation as an indicator of drug effect, has been used to comparatively assess the chemosensitivity of different tumor lesions from the same patient. The analysis was performed on primary tumors and their synchronous metastases from 67 patients with breast, ovarian, gastrointestinal and germ cell testicular tumors. A remarkable difference in sensitivity to cytostatic drugs was observed between the two lesions. In contrast, a strong association in chemosensitivity (81.7% agreement rate; p less than 0.01) was observed between two synchronous metastases from 17 patients with breast, ovarian, germ cell testicular tumors or malignant melanoma. In addition, the predictive relevance of the antimetabolic assay on clinical response to chemotherapy was analyzed in relation to the type of tumor lesion tested in vitro in a retrospective correlative study on 57 patients with advanced ovarian and germ cell testicular tumors. The objective clinical response was significantly correlated to the in vitro sensitivity of metastases (83.7% agreement rate; p less than 0.01), but not to that of the primary tumor.
Insights
This study reveals that chemotherapy sensitivity differs between primary tumors and metastases. However, metastases from the same patient show similar drug sensitivity, predicting clinical response.
Area of Science:
- Oncology
- Pharmacology
- Cancer Research
Background:
- Assessing chemosensitivity is crucial for tailoring cancer treatment.
- Tumor heterogeneity can impact treatment efficacy.
- In vitro assays offer a method to predict patient response.
Purpose of the Study:
- To compare the chemosensitivity of primary tumors versus synchronous metastases.
- To evaluate the concordance of chemosensitivity between synchronous metastases.
- To determine the predictive value of an antimetabolic assay for clinical response.
Main Methods:
- A short-term antimetabolic assay measuring [3H]thymidine incorporation was employed.
- Chemosensitivity was assessed in primary tumors and synchronous metastases from 67 patients.
- The assay's predictive relevance was analyzed in 57 advanced cancer patients.
Main Results:
- Significant differences in cytostatic drug sensitivity were found between primary tumors and metastases.
- High agreement (81.7%) in chemosensitivity was observed between synchronous metastases.
- In vitro metastasis sensitivity strongly correlated with objective clinical response (83.7% agreement), unlike primary tumor sensitivity.
Conclusions:
- Metastases exhibit more consistent chemosensitivity profiles than primary tumors.
- In vitro chemosensitivity testing of metastases can predict clinical chemotherapy response.
- This assay may aid in optimizing treatment strategies for advanced cancers.